NCT03986463View on ClinicalTrials.gov

CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility

CompletedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Lung NeoplasmsLung CancerNeoplasm of LungNon Small Cell Lung Cancer
Interventions
OTHER

Circulating tumour DNA (ctDNA)

Circulating tumour DNA (ctDNA) will be isolated from blood samples

Trial Locations (1)

N6A 5W9

London Regional Cancer Program, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT03986463 - CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility | Biotech Hunter | Biotech Hunter